Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.30 |
| ▸ | HPGDS | O60760 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27816024 | 1.00 | NPC1 (0.34) | NPC1RAB9AHDAC3HDAC1HDAC2 | |
| SCHEMBL618237 | 0.88 | NAMPT (0.34) | NPC1RAB9ANAMPT | |
| SCHEMBL16611327 | 0.86 | HDAC3 (0.35) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18988995 | 0.81 | — | — | |
| SCHEMBL15614617 | 0.80 | — | — | |
| SCHEMBL185632 | 0.80 | — | — | |
| SCHEMBL4321186 | 0.80 | — | — | |
| SCHEMBL28138206 | 0.79 | ALDH1A1 (0.33) | NPC1RAB9AHDAC3HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL4325316 | 0.78 | RAB9A (0.40) | NPC1RAB9AHDAC3HDAC1HDAC2 | |
| SCHEMBL27906782 | 0.76 | OPRM1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2982675-B1 | SALT OF PYRAZOLOQUINOLINE DERIVATIVE, AND CRYSTAL THEREOF | EISAI R&D MAN CO LTD (JP) | 2017-08-16 | — | — | EP | disclosed |
| US-9573947-B2 | Salt of pyrazoloquinoline derivative, and crystal thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160046623-A1 | SALT OF PYRAZOLOQUINOLINE DERIVATIVE, AND CRYSTAL THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-02-18 | — | — | US | disclosed |
| EP-2982675-A1 | SALT OF PYRAZOLOQUINOLINE DERIVATIVE, AND CRYSTAL THEREOF | Eisai R&D Management Co., Ltd. (JP) | 2016-02-10 | — | — | EP | disclosed |
| EP-2769980-B1 | PYRAZOLOQUINOLINE DERIVATIVE AS PDE9 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-2769980-A1 | PYRAZOLOQUINOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2014-08-27 | — | — | EP | disclosed |
| US-20130296352-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-8563565-B2 | Pyrazoloquinoline derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| US-20120316150-A1 | AMIDE COMPOUNDS USEFUL IN THERAPY | PFIZER INC. | 2012-12-13 | — | — | US | disclosed |
| US-8232269-B2 | Amide compounds useful in therapy | PFIZER INC. (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2350017-A1 | AMIDE COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| US-20100249091-A1 | Amide Compounds Useful in Therapy | GIBSON KARL RICHARD | 2010-09-30 | — | — | US | disclosed |
| WO-2010032200-A1 | AMIDE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249091-A1 | Amide Compounds Useful in Therapy | PTGER3, PTGER1, PTGER2 | NPC1 3174/4885RAB9A 2122/4885HDAC3 71/4885 |
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | PDE2A, PDE3A, PDE3B | NPC1 1820/4885RAB9A 66/4885HDAC3 1462/4885 |
| US-20120316150-A1 | AMIDE COMPOUNDS USEFUL IN THERAPY | GNRHR, RXFP1, ARG1 | NPC1 4211/4885RAB9A 880/4885HDAC3 21/4885 |
| US-20160046623-A1 | SALT OF PYRAZOLOQUINOLINE DERIVATIVE, AND CRYSTAL THEREOF | ME1, TST, ME3 | NPC1 2924/4885RAB9A 2806/4885HDAC3 1930/4885 |
| US-20130296352-A1 | PYRAZOLOQUINOLINE DERIVATIVES | PDE2A, PDE3A, PDE3B | NPC1 1820/4885RAB9A 66/4885HDAC3 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.